Amarin Corp Plc Surges 25% ahead of expected FDA descision regarding reinstatement of Anchor drug trial on vascepa
- Last year the FDA communicated to Amarin that it now views Amarin's appeal of the ANCHOR SPA agreement rescission and the ANCHOR sNDA as separate administrative decisions worthy of separate consideration. FDA plans to complete its review of Amarin's request to re-instate the ANCHOR SPA agreement and plans to convey its decision to Amarin no later than January 15, 2014.